OncView™ Podcast: Connie Batlevi, MD, PhD on R/R Follicular Lymphoma Therapy Updates

News
Podcast

Connie Batlevi, MD, PhD, detailed important updates in therapies for relapsed/refractory follicular lymphoma in this episode of CancerNetwork’s® podcast.

As part of the OncView video series, CancerNetwork® spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat (Tazverik), and sequencing changes.

In the video series, Batlevi discussed the following:

To watch more videos in CancerNetwork’s® OncView™ series, visit cancernetwork.com/oncview.

Recent Videos
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
It may be critical to sequence BCL-2 inhibitors with BTK inhibitors for patients with mantle cell lymphoma in the relapsed/refractory setting.
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
Related Content
Boston’s Best Did Not “Leave the Cannoli” in Battle of Lymphoma Top Trials

Boston’s Best Did Not “Leave the Cannoli” in Battle of Lymphoma Top Trials

ONCOLOGY Staff
September 25th 2025
Article

Two teams of lymphoma experts engage in a face-off competition, showcasing real-world updates, patient cases, and use of ASCT or CAR T-cell therapy.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Regarding safety, treatment-related adverse effects occurred in 93% of patients, with grade 3 or 4 TRAEs occurring in 60%.

Mosunetuzumab Treatment Combo Yields Responses in High-Risk MCL

Tim Cortese
September 21st 2025
Article

Michael Wang, MD, stated that results from this phase 2 trial were tremendous and showed that mosunetuzumab plus polatuzumab vedotin is viable in MCL.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 8th 2025
Article

Results from the phase 3 BRUIN CLL-313 trial show that OS trended favorably for pirtobrutinib vs chemoimmunotherapy in this CLL and SLL population.